Results 81 to 90 of about 1,181 (167)

Arzneimittelpreise: Den Forderungen nicht nachgeben! [PDF]

, 2011
Greß, Stefan
core   +3 more sources

Ordnungspolitisches Nirwana: Gesundheitspolitik [PDF]

, 2011
Jacobs, Klaus
core   +3 more sources

EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making. [PDF]

J Mark Access Health Policy
Johns A, Andrade A, Johal S, Ryan J.
europepmc   +1 more source

Comment on: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Gandjour A.
europepmc   +1 more source

Authors' Reply to Gandjour: "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?" [PDF]

Appl Health Econ Health Policy
Büssgen M, Stargardt T.
europepmc   +1 more source

Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: a retrospective cohort study. [PDF]

Lancet Reg Health Eur
Müller G, Granold M, Busse R, Hahn A.
europepmc   +1 more source

Availability of New Medicines in the US and Germany From 2004 to 2018.

JAMA Netw Open, 2022
Blankart K, Naci H, Chandra A.
europepmc   +1 more source

Fampridin laut AMNOG erstattungsfähig [PDF]

DNP - Der Neurologe und Psychiater, 2013
openaire   +1 more source

I tetti sulla spesa per i farmaci nel quadro delle azioni di governo dell’assistenza farmaceutica: criticità e opzioni per una riforma. [PDF]

Glob Reg Health Technol Assess
Jommi C.
europepmc   +1 more source